SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Kwality Pharma - Quaterly Results

10 Aug 2023 Evaluate
Revenue reduced marginally to stand at Rs. 674.50 millions during the quarter ended June 2023. The figure stood at Rs. 702.19 millions during the year-ago period.A big decline of -48.38% was reported for the quarter ended June 2023 to Rs. 54.46  millions from Rs. 105.50 millions of corresponding previous quarter.The Operating Profit of the company witnessed a decrease to 142.04 millions from 184.00 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202306 202206 % Var 202306 202206 % Var 202303 202203 % Var
Sales 674.50 702.19 -3.94 674.50 702.19 -3.94 2509.95 4561.32 -44.97
Other Income 3.96 3.77 5.04 3.96 3.77 5.04 29.41 35.12 -16.26
PBIDT 142.04 184.00 -22.80 142.04 184.00 -22.80 632.29 1752.37 -63.92
Interest 21.85 12.19 79.25 21.85 12.19 79.25 60.20 29.17 106.38
PBDT 120.19 171.81 -30.04 120.19 171.81 -30.04 406.80 1723.20 -76.39
Depreciation 47.79 31.31 52.63 47.79 31.31 52.63 149.19 106.44 40.16
PBT 72.40 140.50 -48.47 72.40 140.50 -48.47 257.61 1616.76 -84.07
TAX 17.94 35.00 -48.74 17.94 35.00 -48.74 62.92 416.28 -84.89
Deferred Tax -0.29 0.00 0.00 -0.29 0.00 0.00 1.37 2.75 -50.18
PAT 54.46 105.50 -48.38 54.46 105.50 -48.38 194.69 1200.48 -83.78
Equity 103.76 103.76 0.00 103.76 103.76 0.00 103.76 103.76 0.00
PBIDTM(%) 21.06 26.20 -19.64 21.06 26.20 -19.64 25.19 38.42 -34.43

Kwality Pharma Share Price

1650.90 -13.40 (-0.81%)
21-Apr-2026 11:39 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1667.00
Dr. Reddys Lab 1219.80
Cipla 1230.95
Zydus Lifesciences 927.80
Lupin 2320.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×